View All Cancer Treatments

Immunotherapy


at the Abramson Cancer Center

Empowering the Immune System to Kill Cancer

CANCER BREAKTHROUGH: FDA Approves CAR T

In a landmark decision for the field of cancer immunotherapy, the FDA approved a CAR-T cell therapy created by Penn Medicine for the treatment of patients up to 25 years old with acute lymphoblastic leukemia.
View more news stories

Call 215-316-5127
or

Changing How the World Fights Cancer

With the discovery of the first gene therapy to be approved by the FDA, Penn Medicine is leading the world in immunotherapy research. Our researchers are working relentlessly to realize the full potential of this innovative approach: reprogramming the body’s own immune cells to seek and destroy every last cancer cell.

One way that we’re doing this is through an immunotherapy treatment option called CAR-T cell therapy. A personalized cellular therapy, it teaches the body’s immune systems to recognize and kill cancer cells.

CAR-T cell therapy has become a powerful addition to Penn’s cancer-fighting arsenal of surgery, targeted therapies, and precision radiation treatments. We have treated nearly 500 blood cancer patients in CAR-T clinical trials.

For more information, call 215-316-5127 or request a call-back today.

Dr. Bruce Levine, Bill Ludwig, Darla Ludwig, and Dr. Carl June

The Breakthrough Started with Bill

For 10 years, Bill Ludwig lived with an enemy determined to take his life: chronic lymphocytic leukemia or CLL, a cancer that starts in the bone marrow. He was given one more weapon to try before he was out of options: a clinical trial using CAR-T cell immunotherapy. 

Bill became the first person to participate in the clinical trial, and seven years later, its success has led to FDA approval of the personalized cellular therapy and countless lives saved.

Read more about Bill

Additional Cutting-Edge Immunotherapy Treatments at Penn

Our dynamic research program is always growing. In addition to CAR-T cell therapy, we focus on other types of immunotherapy research, such as vaccine therapy and checkpoint inhibitors.

Donate to Support Immunotherapy Research

Our success with CAR-T cell therapy is all thanks to the help we’ve received from our partners, researchers, philanthropists, and fellow cancer visionaries. Donate today, so we can continue creating immunotherapy treatments to put more and more people in remission.